1. Supportive Care in the Treatment of Lower-Risk Myelodysplastic Syndromes

2. MDS: Introduction

3. 2016 WHO Classification of Myeloid Neoplasms

4. Discrepancy in Diagnosis of MDS Between Treatment Centers

5. IPSS and IPSS-R

6. MD Anderson Model of Prognosis for Patients With LR MDS

7. CHIP

8. Case Study: Discussion

9. Supportive Care Asymptomatic Patients

10. Low-Dose Decitabine vs Low-Dose Azacitidine in LR/Int-1-Risk MDS

11. Does Early Intervention Help Patients with LR MDS?

12. Low-Dose Decitabine vs Low-Dose Azacitidine in LR/Int-1-Risk MDS

13. MD Anderson Model of Prognosis for Patients With LR MDS

14. NCCN 2017 LR/Int-1-Risk MDS With Symptomatic Anemia

15. Impact of Comorbidities by ACE-27 in the IPSS-R for MDS

16. Cytogenetic Groups of MDS

17. Goals of Therapy for LR MDS

18. Predictive Model for Response to Treatment With EPO + G-CSF

19. TELESTO Deferasirox in LR/Int-1 MDS With Transfusional Iron Overload

20. MDS-002/003 Lenalidomide in MDS

21. Lenalidomide vs Placebo in RBC Transfusion-Dependent LR MDS

22. Low-Dose HMAs in LR MDS

23. QUAZAR Azacitidine and BSC vs Placebo and BSC

24. Ongoing Clinical Trials in LR MDS

25. Thrombocytopenia in MDS

26. Conclusions

27. Abbreviations

28. Abbreviations (cont)

29. Abbreviations (cont)

30. Abbreviations (cont)